Parabolic Drugs Limited– IPO Note - ANS Pvt. Ltd.

More documents

Recommendations

Info

The Indian CRAMS IndustryIndia is emerging as one of the most attractive destinations for outsourcing of globalpharmaceutical activities.The Indian CRAMS industry was valued at USD 1.7 billion in 2008. Despite India’s inherentadvantages, it accounts for only ~3% share of the USD 51 billion global outsourcing market,indicating significant opportunity for growth in this segment.Source: Company RHP
POSITIVES AND CONCERNS ABOUT THE COMPANYPositivesRobust GrowthThe company’s revenues have grown at a CAGR of more than 65% over last 4 years. Also, theproposed future expansion plans will result in continuous growth in top line of the company.High Asset TurnoverThe company asset turn over ratio is highest among its peers which allow PDL to manage itscapital efficiently.Exclusive ContractsThe company made a contract with Ranbaxy for two of its molecules, to provide bulk drugs.Such contracts with larger Pharma players could boost PDL’s earning prospects in coming years.Private Equity Firms partly exitThe two PE firms Alden Global and BTS India Private Equity are only taking a partial exit. Boththe PE firms remain invested which may signal possibility of generating higher returns in thenear future.
Page 2 and 3: Issue DetailsSectorPharmaceuticalIs
Page 4 and 5: INDUSTRY OUTLOOKINDIAN PHARMACEUTIC
Page 8 and 9: ConcernsNegative Operating Cash flo
Page 10 and 11: FINANCIAL HIGHLIGHTS1. Total income
Page 12 and 13: -Die Wirtschaftsgebäude: die Bauh

Parabolic Drugs Limited– IPO Note - ANS Pvt. Ltd.

Create successful ePaper yourself

Delete template?

Save as template?